Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2568
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting ; day:11 ; month:10 ; year:2018 ; pages:1-8
Digestive diseases and sciences ; (11.10.2018), 1-8
- Creator
-
Checkley, L. Allyson
- Contributor
-
Kristofek, Loretta
Kile, Samantha
Bolgar, William
SpringerLink (Online service)
- DOI
-
10.1007/s10620-018-5319-6
- URN
-
urn:nbn:de:101:1-2018111919315131674734
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Checkley, L. Allyson
- Kristofek, Loretta
- Kile, Samantha
- Bolgar, William
- SpringerLink (Online service)
Other Objects (12)
Predictors of infusion reactions during infliximab treatment in patients with arthritis
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study
Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study
Alternate Currents
Alternate control systems
Incidence of Hypersensitivity Reactions During Hemodialysis
First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
Predictors of infusion reactions during infliximab treatment in patients with arthritis
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study
Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study
Alternate Currents
Alternate control systems
Incidence of Hypersensitivity Reactions During Hemodialysis
First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
Predictors of infusion reactions during infliximab treatment in patients with arthritis
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study
Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study
Alternate Currents
Alternate control systems
Incidence of Hypersensitivity Reactions During Hemodialysis
First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report